S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Sports analytics may be outnumbered when it comes to artificial intelligence
Critical asset just had biggest fall on record (Ad)
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
California authorizes expansion of Waymo's driverless car services to LA, SF peninsula
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
College athletes will need school approval for NIL deals under bill passed by Utah Legislature
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Sports analytics may be outnumbered when it comes to artificial intelligence
Critical asset just had biggest fall on record (Ad)
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
California authorizes expansion of Waymo's driverless car services to LA, SF peninsula
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
College athletes will need school approval for NIL deals under bill passed by Utah Legislature
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Sports analytics may be outnumbered when it comes to artificial intelligence
Critical asset just had biggest fall on record (Ad)
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
California authorizes expansion of Waymo's driverless car services to LA, SF peninsula
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
College athletes will need school approval for NIL deals under bill passed by Utah Legislature
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Sports analytics may be outnumbered when it comes to artificial intelligence
Critical asset just had biggest fall on record (Ad)
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
California authorizes expansion of Waymo's driverless car services to LA, SF peninsula
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
College athletes will need school approval for NIL deals under bill passed by Utah Legislature

Bluejay Diagnostics (BJDX) Competitors

$0.82
+0.03 (+3.80%)
(As of 03/1/2024 ET)

BJDX vs. NVIV, SINT, MOTS, RSLS, NH, NMRD, INVO, DYNT, IONM, and TNON

Should you be buying Bluejay Diagnostics stock or one of its competitors? The main competitors of Bluejay Diagnostics include InVivo Therapeutics (NVIV), Sintx Technologies (SINT), Motus GI (MOTS), ReShape Lifesciences (RSLS), NantHealth (NH), Nemaura Medical (NMRD), INVO Bioscience (INVO), Dynatronics (DYNT), Assure (IONM), and Tenon Medical (TNON). These companies are all part of the "medical" sector.

Bluejay Diagnostics vs.

InVivo Therapeutics (NASDAQ:NVIV) and Bluejay Diagnostics (NASDAQ:BJDX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

13.8% of InVivo Therapeutics shares are held by institutional investors. Comparatively, 17.5% of Bluejay Diagnostics shares are held by institutional investors. 2.5% of InVivo Therapeutics shares are held by company insiders. Comparatively, 47.0% of Bluejay Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Bluejay Diagnostics has higher revenue and earnings than InVivo Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InVivo TherapeuticsN/AN/A-$10.49MN/AN/A
Bluejay Diagnostics$250K4.07-$9.30M-$9.63-0.09

InVivo Therapeutics has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. Comparatively, Bluejay Diagnostics has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500.

InVivo Therapeutics received 228 more outperform votes than Bluejay Diagnostics when rated by MarketBeat users. However, 66.67% of users gave Bluejay Diagnostics an outperform vote while only 56.65% of users gave InVivo Therapeutics an outperform vote.

CompanyUnderperformOutperform
InVivo TherapeuticsOutperform Votes
230
56.65%
Underperform Votes
176
43.35%
Bluejay DiagnosticsOutperform Votes
2
66.67%
Underperform Votes
1
33.33%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InVivo Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Bluejay Diagnostics
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Bluejay Diagnostics' return on equity of -75.04% beat InVivo Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
InVivo TherapeuticsN/A -75.04% -65.01%
Bluejay Diagnostics N/A -123.99%-97.34%

In the previous week, Bluejay Diagnostics had 1 more articles in the media than InVivo Therapeutics. MarketBeat recorded 2 mentions for Bluejay Diagnostics and 1 mentions for InVivo Therapeutics. InVivo Therapeutics' average media sentiment score of 1.44 beat Bluejay Diagnostics' score of 0.00 indicating that Bluejay Diagnostics is being referred to more favorably in the news media.

Company Overall Sentiment
InVivo Therapeutics Neutral
Bluejay Diagnostics Positive

Summary

Bluejay Diagnostics beats InVivo Therapeutics on 8 of the 11 factors compared between the two stocks.


Get Bluejay Diagnostics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BJDX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BJDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BJDX vs. The Competition

MetricBluejay DiagnosticsSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$1.02M$3.79B$5.20B$7.62B
Dividend YieldN/A1.88%2.82%3.87%
P/E Ratio-0.0913.82206.0316.04
Price / Sales4.0726.353,031.0680.30
Price / CashN/A26.0699.1555.35
Price / Book0.074.164.524.54
Net Income-$9.30M$19.30M$114.88M$211.55M
7 Day Performance9.33%3.19%5.69%3.36%
1 Month Performance5.13%4.45%11.23%6.68%
1 Year Performance-94.01%1.53%14.04%8.85%

Bluejay Diagnostics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NVIV
InVivo Therapeutics
0 of 5 stars
N/AN/AN/A$997,000.00N/A0.006Analyst Report
Gap Down
SINT
Sintx Technologies
0 of 5 stars
$0.15
flat
N/A-94.7%$786,000.00$1.56M0.0041Gap Up
MOTS
Motus GI
2.1978 of 5 stars
$0.65
+1.6%
$28.88
+4,326.6%
-94.9%$450,000.00$590,000.00-0.0243Short Interest ↑
High Trading Volume
RSLS
ReShape Lifesciences
0.7406 of 5 stars
$0.17
-5.7%
$8.00
+4,728.0%
-95.8%$2.18M$11.24M0.0040News Coverage
High Trading Volume
NH
NantHealth
0 of 5 stars
$0.29
-3.4%
N/A-89.4%$2.20M$67.68M-0.04326Analyst Report
Gap Down
NMRD
Nemaura Medical
2.199 of 5 stars
$0.08
-11.6%
$4.25
+5,492.1%
-91.8%$2.20M$80,000.00-0.1936Gap Down
INVO
INVO Bioscience
0 of 5 stars
$0.94
+6.8%
N/A-90.1%$2.32M$820,000.00-0.0815Short Interest ↓
DYNT
Dynatronics
1.836 of 5 stars
$0.49
flat
$3.80
+683.5%
-74.3%$2.37M$40.61M-0.35154Analyst Report
Short Interest ↓
Gap Down
IONM
Assure
1.5044 of 5 stars
$0.35
+12.8%
$8.00
+2,166.3%
-94.2%$2.37M$10.85M0.00127Short Interest ↑
Gap Down
High Trading Volume
TNON
Tenon Medical
1.9967 of 5 stars
$1.08
-11.5%
$6.00
+455.5%
-46.1%$2.67M$2.40M-0.0722Gap Up

Related Companies and Tools

This page (NASDAQ:BJDX) was last updated on 3/2/2024 by MarketBeat.com Staff